Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease.

Salil Vasudeo DeoDavid McAllisterSharon LaForestSalah AltarabshehYakov E ElgudinShannon DunlaySimerpreet SinghSahil ParikhNaveed SattarJill P Pell

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)

Adjusted for LDL-C levels, PAD and CeVD patients are much less likely to receive PCSK9i therapy. Despite low co-pay, PCSK9i initiation rates among US veterans, nationwide, is low, with household income and community deprivation appearing to predict PCSK9i use.

Keyphrases

low density lipoprotein
end stage renal disease
mental health
ejection fraction
chronic kidney disease
newly diagnosed
healthcare
peritoneal dialysis
prognostic factors
physical activity
health insurance
patient reported outcomes
replacement therapy
affordable care act